Sudarshan Pharma Industries Limited has announced a board meeting scheduled for January 28, 2026, to review and approve the company's quarterly financial performance. The pharmaceutical company informed BSE Limited about this development through an official communication dated January 22, 2026.

Board Meeting Details

The Board of Directors will convene on Wednesday, January 28, 2026, with the primary agenda being the consideration and approval of unaudited financial results for the quarter ended December 31, 2025. The meeting will cover both standalone and consolidated financial statements for the third quarter of FY26.

Regulatory Compliance

The announcement has been made pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about board meetings where financial results will be considered, ensuring transparency and timely disclosure to investors and stakeholders.

Trading Window Restrictions

Sudarshan Pharma Industries has notified that the company's trading window will continue to remain closed until 48 hours after the declaration of the financial results for the quarter ended December 31, 2025. This measure is implemented to prevent insider trading and ensure fair market practices during the period when price-sensitive information is being processed and disclosed.

Company Information

Sudarshan Pharma Industries Limited operates from its head office located at 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092. The company is listed on BSE with scrip code 543828 and trades under the symbol SUDARSHAN. The official communication was signed by Nirav Shah, Company Secretary and Compliance Officer, emphasizing the company's commitment to regulatory compliance and transparent corporate governance practices.

Sudarshan Pharma Industries has announced the establishment of a fully owned subsidiary in Poland, marking a strategic milestone in the company's European market expansion plans. This development represents a significant step forward in the pharmaceutical company's international growth strategy.

Strategic European Expansion

The establishment of the Poland subsidiary demonstrates Sudarshan Pharma Industries' commitment to strengthening its presence in the European pharmaceutical market. Poland serves as a strategic location for accessing broader European markets and establishing a stronger foothold in the region.

Market Positioning

The Poland subsidiary positions Sudarshan Pharma Industries to better serve European customers and expand its pharmaceutical operations across the continent. This move aligns with the company's broader strategy to diversify its geographical presence and reduce dependence on domestic markets.

Business Implications

The establishment of this European subsidiary reflects the company's confidence in international market opportunities and its ability to execute cross-border expansion strategies. The Poland location provides access to European Union markets and regulatory frameworks, potentially facilitating broader regional growth initiatives.

This strategic development marks an important phase in Sudarshan Pharma Industries' evolution from a domestic-focused pharmaceutical company to one with international operations and market presence.